Compass Therapeutics (NASDAQ:CMPX) Now Covered by D. Boral Capital

D. Boral Capital started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $32.00 target price on the stock.

CMPX has been the subject of several other research reports. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Monday, September 16th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $1.51 on Monday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The stock has a market cap of $207.76 million, a PE ratio of -4.08 and a beta of 0.89. The firm has a 50-day simple moving average of $1.65 and a 200 day simple moving average of $1.41.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Research analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently modified their holdings of CMPX. Renaissance Technologies LLC raised its holdings in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares in the last quarter. Rhumbline Advisers increased its position in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after purchasing an additional 12,315 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $68,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $41,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Compass Therapeutics in the third quarter valued at $79,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.